<DOC>
	<DOCNO>NCT02846324</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled trial eligible IPF subject randomize receive GBT440 Placebo orally daily .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability GBT440 Administered Subjects With IPF</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Documented diagnosis IPF . Oxygen desaturation exercise . Completion baseline 6MWT Weight â‰¥ 50 kg Male female child bear potential willing able use highly effective method contraception study start 3 month last dose study drug . FEV1/FVC &lt; 70 % . Subjects supplemental oxygen therapy rest . History interstitial lung disease . Significant polycythemia . Female breastfeed pregnant . Known current malignancy history malignancy within last 2 year prior screen . Use cytotoxic and/or immunosuppressant medication within 30 day screen . Hospitalization due exacerbation IPF within 30 day screen Subject plan begin commence pulmonary rehabilitation within 30 day screen Corticosteroids ( &gt; 10 mg per day prednisone equivalent ) within 30 day screen . Current smoker history smoking within 3 month screen . Currently , opinion investigator , soon list lung transplant . History unstable deteriorate cardiac pulmonary disease ( IPF ) within 6 month screen . Any condition possibly affect drug absorption . Participated another clinical trial investigational drug ( medical device ) within 30 day 5halflives , whichever longer , prior screen , currently participate another trial investigational drug ( medical device ) . Subject , reason , deem investigator inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>